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with serum ferritin in HCV-infected patients and further in-Elevation of blood thioredoxin in hemodialysis patients with
creased by iron infusion. These findings indicate that HCVhepatitis C virus infection.
infection and iron loading may aggravate oxidative stress inBackground. Thioredoxin (TRX) is a stress-inducible thiol-
dialysis patients.containing protein, which has been shown to be an indicator
of oxidative stress in a variety of diseases. The association
between oxidative stress and hepatitis C virus (HCV) infection,
however, remains unknown in hemodialysis patients.
The prevalence of hepatitis C virus (HCV) infectionMethods. We measured serum TRX levels in 85 hemodialy-
is known to be much higher in hemodialysis patientssis patients positive for anti-HCV antibodies (age, 60 1 years
old; hemodialysis duration, 17  1 years; M/F  57/28) by than in the normal population, with an incidence of about
enzyme-linked immunosorbent assay (ELISA), and examined 20% [1]. HCV infection results in liver cirrhosis in 8.6%
whether blood TRX may be associated with HCV-related he- of hemodialysis patients and hepatocellular carcinomapatic injury.
(HCC) in 1.8% [2], which could contribute to the higherResults. Serum TRX was significantly higher in hemodialysis
mortality in HCV-positive hemodialysis patients [1].patients with HCV infection (112.3  3.7 ng/mL, N  85) than
in those without HCV infection (69.7  3.3 ng/mL, N  59) Hemodialysis patients are chronically exposed to oxida-
(age, 69  2 years old; hemodialysis duration, 6  1 years; tive stress from reactive oxygen species. Excess oxidative
M/F  32/27, P  0.01) or normal subjects (28.0  5.4 ng/mL, stress is associated with arteriosclerosis, erythropoietinN 9). TRX was significantly correlated with time on hemodi-
(rHuEPO) resistance, and malnutrition in dialysis pa-alysis (r  0.27, P  0.01) in HCV-positive patients, while it
tients [3]. Although a higher level of blood malondialde-was associated with the patient’s age in HCV-negative patients
(r  0.42, P  0.01). Blood TRX was significantly correlated hyde (MDA) was noticed in HCV-positive hemodialysis
with asparate aminotransferase in patients with HCV infection patients, compared to HCV-negative patients, in a small
(r  0.34, P  0.01) and without HCV infection (r  0.46, P 
study [4], the relationship between oxidative stress and0.01). However, serum TRX was not associated with blood
chronic HCV infection remains to be fully determined.alanine aminotransferase, a relatively specific marker of he-
patic cellular damage, in HCV-infected hemodialysis patients. Thioredoxin (TRX) is a ubiquitous protein (12 kD mo-
A significant relationship was found between serum ferritin and lecular weight) with a three-dimensional structure contain-
TRX (r 0.25, P 0.02) and malondialdehyde (MDA) values ing two redox-active cysteine residues (Cys-32-Gly-Pro-(r  0.25, P  002) in HCV-positive patients. Serum TRX was
Cys-35). Recent experimental studies show that TRX isalso higher in the patients receiving weekly iron supplement
released from cells in response to oxidative stress [5]with HCV infection (135.3 10.2 ng/mL vs. 110.2 3.9 ng/mL,
P  0.06) and without HCV infection (91.8  12.1 ng/mL vs. and plays a protective role against oxidant injury [6]. For
65.2  2.7 ng/mL, P  0.01). example, intracellular TRX scavenges reactive oxygen
Conclusion. There was a greater increase in serum TRX in
species and regulates redox-sensitive transcriptional fac-hemodialysis patients with HCV viremia than without HCV
tors such as activator protein-1 and nuclear factor-Bviremia. However, there may not be an association between
serum TRX and HCV-related hepatic injury. TRX increased (NF-B) [7]. Infusion of human TRX ameliorated exper-
imental ischemic pulmonary injury [8] and overexpres-
sion of TRX in transgenic mice attenuated ischemic andKey words: thioredoxin, hepatitis C virus, iron, oxidative stress, hemo-
dialysis. oxidative injury [9, 10].
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variety of diseases, including collagen vascular diseases, Medical, Tokyo, Japan or APA, Asahi Medical, Tokyo,
Japan). Each patient had been using the same dialyzermalignancy, burns, diabetes, and heart failure, and it is
associated with the severity of the disease [13–17]. These membrane for more than 1 year. There was no patient
who reused the dialyzer membrane. Based upon endo-findings convincingly suggest that TRX is secreted into
the circulation in response to oxidative stress in many toxin removal filter, the endotoxin concentration in the
dialysate was below 20 EU/L by routine analysis withdiseases.
The aim of the present study is to determine whether Limulus amebocyte lysate assay (Wako Junyaku Endo-
toxin Measurement Kit, Tokyo, Japan).serum TRX, a marker of oxidative stress, may be in-
creased in hemodialysis patients with HCV-related hepa- Blood samples were obtained from the arterial site of
arteriovenous fistula both at the start and at the end oftitis. We first measured serum TRX in hemodialysis pa-
tients with or without HCV viremia. Next, we examined the dialysis session, 2 days after the last hemodialysis
session. Serum was transferred into plastic tubes andthe association between blood TRX and other laboratory
parameters in patients with chronic HCV hepatitis. Fi- stored at –80C until assayed.
We routinely measured blood ferritin every 3 months,nally, we examined the relationship between blood TRX,
iron storage, and intravenous iron supplementation. and determined the need for iron supplementation ac-
cording to the following criteria: when ferritin and hema-
tocrit levels were reduced below 100 ng/mL and 30%,
METHODS
respectively, intravenous injection of chondroitin sulfate
Study population colloid containing 40 mg of elemental iron (BultalR; Chu-
gai Pharmaceutical Co., Ltd., Tokyo, Japan) was initiatedWe selected 85 hemodialysis patients who were posi-
tive for anti-HCV antibody from two dialysis units (N  at the end of the hemodialysis session once a week during
the next 3 months. At the start of this study, seven pa-395, Maruyama Hospital and Maruyama Clinic, Hama-
matsu, Japan). The rate of anti-HCV antibody positive tients with HCV infection (8.2%) and 10 without HCV
infection (16.9%) had received intravenous iron supple-patients was 21.5%. The study patients included 57 men
and 28 women, with a mean age of 60 (24 to 82) years ment during the recent 3 months.
old. The mean time on hemodialysis was 17 years, with
Analytical proceduresa range of 1 to 30 years. About 70% of the patients had
received hemodialysis treatment for more than 10 years. Serum asparate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (Al-p), -gluta-Fifteen patients (17.6%) had diabetes. Neither abdomi-
nal echography nor noncontrast computed tomography myl transpeptidase (-GTP), urea nitrogen, creatinine,
total protein, albumin, and hemoglobin were measureddisclosed any obvious HCC in any patient. We also se-
lected 59 hemodialysis patients without HCV infection by standard laboratory techniques using an automatic
analyzer. C-reactive protein was measured by laser neph-as a HCV-negative control group (age, 69  2 years old;
hemodialysis duration, 6 1 years; male/female 32/27). erometer. The concentrations of intact parathyroid hor-
mone (PTH) and ferritin were measured using a sand-No patient had HIV infection, congestive heart failure,
malignancy, or collagen vascular disease at the entry into wich enzyme immunoassay (SphereLight 180, Wako
Junyaku, Osaka, Japan). Blood -fetoprotein (AFP) wasthis study. Individuals with a history of alcohol abuse or
receiving potentially hepatotoxic drugs were not in- determined using a liquid-phase binding assay (Sphere-
Light 180, Wako Junyaku, Osaka, Japan). Protein in-cluded in this study. No patient was receiving hyperali-
mentation at the start of this study. duced by vitamin K absence or antagonism (PIVKA-II)
levels were determined by an enzyme immunoaasay with
Hemodialysis procedures an anti-deoxycytidimine triphosphate (DCP) monoclonal
antibody (EI-test mono-P, Eisai laboratory, Tokyo, Ja-All patients received regular hemodialysis for 4 to 5
hours, three times per week, with a blood flow rate of 180 pan) and measured with the same kit. Normal ranges of
serum AFP and PIVKA-II are below 10 ng/mL and 40to 220 mL/min using bicarbonate dialysate (30 mEq/L,
Kindaly AF-2P, Fuso, Osaka, Japan). All hemodialysis mAU/mL, respectively. The presence of anti-HCV anti-
bodies was measured with a third-generation kit (Ortho-treatments were performed using one of the following
membranes: low-flux ultrafiltration rate (UFR) (20 ml/ Clinical Diagnostics, Emeryville, CA, USA), and serum
HCV RNA was detected by reverse transcription poly-min/hour) modified regenerated cellulose (MRC) hollow-
fiber (AM-SD, Asahi Medical, Tokyo, Japan, or CL-EE, merase chain reaction (RT-PCR). Serum TRX was mea-
sured using a sensitive sandwich enzyme-linked immuno-Terumo, Tokyo, Japan), medium-flux (UFR 20 to 40 mL/
min/hour) cellulose triacetate (CTA) hollow-fiber (FB-U, sorbent assay (ELISA) kit as described previously [12–17].
Serum MDA was determined spectrophotometrically byNipro Medical, Osaka, Japan, or TFW, Teijin-Gambro,
Tokyo, Japan), or high-flux (UFR 40mL/min/hour) measurement of thiobarbituric acid reactant (normal range,
1.8 to 4.7 nmol/mL, SRL, Tokyo, Japan). Dialysis efficiencypolysulfone synthetic (PS) hollow-fiber (BS-U, Toray
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on hemodialysis, 3  1 years; N  26) than in HCV-
negative patients (P  0.01). In contrast, serum TRX
was identical between diabetic and nondiabetic patients
both in HCV-infected (111.8  7.2 ng/mL vs. 112.4 
4.3 ng/mL) and noninfected patients (65.4  4.4 ng/mL
vs. 71.8  4.3 ng/mL).
In HCV-infected patients, there was a significant posi-
tive relationship between serum TRX and time on hemo-
dialysis (r  0.27, P  0.02). This significant association
was also observed in nondiabetic patients (r  0.36, P 
0.01, N  70). In contrast, no relationship was found
between duration of hemodialysis and TRX in patients
Fig. 1. Serum thioredoxin (TRX) in hemodialysis (HD) patients. A without HCV viremia.
significant increase in blood TRX is present in HD patients without Age was significantly correlated with serum TRX inhepatitis C virus (HCV) infection compared to normal subjects. TRX
patients without HCV viremia (r  0.42, P  0.01). Agewas increased to a greater extent in patients with HCV infection than
those without HCV infection. was also positively correlated with TRX in nondiabetic
uninfected subjects (r  0.56, P  0.01, N  40). In
contrast, there was no association between age and TRX
in HCV-positive patients.
was assessed based on the delivered dose of dialysis (Kt/ TRX was not associated with nutritional parameters
Vurea) using a single-pool urea kinetic model. Protein such as albumin, creatinine, and blood urea nitrogen
catabolic rate (PCR), an indirect indicator of protein (BUN), either in HCV-positive or HCV-negative pa-
intake, was calculated from dialysis urea removal and tients. Similarly, TRX did not correlate with blood hemo-
serum urea levels. globin, C-reactive protein or measures of hemodialysis
efficacy, such as Kt/Vurea and urea reduction ratio.Statistical analysis
Each value was expressed as the mean SE. A P value Serum TRX and chronic HCV infection
less than 0.05 was considered statistically significant. The In our patients, blood AFP levels in HCV-positive pa-
difference between two groups was analyzed by Student tients were 2.9  0.3 ng/mL, with a range from 0.3 to 21.1
t test. A multiple stepwise regression analysis was used to ng/mL. Only one patient exceeded the normal range (10
examine the relationship between TRX and 11 factors: ng/mL). Blood PIVKA-II, a specific marker of HCC,
age, time on hemodialysis, use of iron infusion, creati- was also within the normal range (40 mAU/mL) in all
nine, C-reative protein, albumin, hemoglobin, ferritin, HCV-positive patients [17  1 (10 to 37) mAU/mL).
intact PTH, Kt/Vurea, and PCR. All statistical calculations Thus, we could not find evidence for HCC in these patients.
were performed with STAT-View software (SAS Insti- HCV-positive patients were significantly younger and
tute, Inc., Cary, NC, USA). had a significantly longer time on hemodialysis than HCV-
negative patients (P  0.01, Table 1). Gender and the
prevalence of diabetes were identical between two groups.RESULTS
A significant increase in blood BUN, creatinine, phos-
Blood TRX in hemodialysis patients phorous, total protein, albumin, and hemoglobin was found
Serum TRX was significantly higher in hemodialysis in patients with HCV infection, indicating that HCV-
patients [94.8  3.1 (37.0 to 216.9); median, 90.4 ng/mL; infected patients were not malnourished (Table 1). In
N  144] than normal subjects [28.0  5.4 (12.8 to 59.0); addition, C-reactive protein was lower in HCV-infected
median, 21.4 ng/mL; N  9] (P  0.01). Blood TRX was patients.
not associated with gender. In contrast, a significantly Serum aminotransferases and -GTP were signifi-
higher TRX was found in HCV-positive patients (112.3 cantly higher in patients with HCV infection than those
3.7; median, 107.9 ng/mL; N  85) than HCV-negative without HCV infection. Blood platelet count was signifi-
patients (69.7  3.3; median, 61.4 ng/mL; N  59) (P  cantly reduced in HCV-positive patients (Table 1). In
0.01) (Fig. 1). Blood TRX was also significantly increased all hemodialysis patients (N  144), blood TRX was
compared to HCV-negative patients who had been on significantly and positively correlated with AST (r 
hemodialysis for more than 6 years (71.6  6.1 ng/mL; 0.46, P  0.01), ALT (r  0.36, P  0.01), Al-p (r 
age, 69 3 years old; time on hemodialysis, 12 1 years; 0.27, P 0.01) and -GTP (r 0.27, P 0.01). However,
N  20). Similarly, blood TRX was significantly higher only AST was significantly correlated with TRX level in
in HCV-positive patients on hemodialysis for less than both HCV-positive (r  0.34, P  0.01) and HCV-nega-
tive (r  0.46, P  0.01) patients (Fig. 2). Blood TRX10 years (99.8  6.3 ng/mL; age, 65  3 years old; time
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Table 1. Clinical parameters in hepatitis C virus (HCV)-positive and HCV-negative hemodialysis patients
HCV Positive Negative P
Number 85 59
Age years 601 692 0.01
Male/Female 57/28 32/27 NS
Time on hemodialysis treatment years 171 61 0.01
Prevalence of diabetes % 17.6 32.2 NS
Iron supplementation % 8.2 18.6 NS
Dialysis and nutrition-related factors
Creatinine mg/dL 11.20.2 10.30.4 0.05
Blood urea nitrogen mg/dL 75.21.6 70.02.0 0.05
Calcium mEq/L 4.70.1 4.60.1 NS
Phosphate mg/dL 5.60.1 5.10.2 0.05
Intact PTH pg/mL 31731 23327 0.05
Hemoglobin g/dL 10.90.1 10.10.1 0.01
Kt/Vurea 1.270.03 1.300.03 NS
Urea reduction rate % 70.91.0 72.10.7 NS
PCR g/kg/day 1.040.02 0.990.02 NS
Albumin g/dL 3.90.03 3.80.03 0.05
CRP mg/dL 0.260.06 0.510.13 0.05
Iron-related factors
Ferritin ng/mL 24642 28039 NS
Iron lg/dL 653 594 NS
TIBC lg/dL 2355 2125 0.01
Transferrin saturation % 28.71.2 28.31.9 NS
Hepatitis-related factors
AST IU/L 211 141 0.01
ALT IU/L 222 101 0.01
Alkaline phosphatase IU/L 26518 22113 NS
-GTP IU/L 354 202 0.01
Platelet 	 104/mm2 15.50.7 19.60.8 0.01
HCV RNA KIU/mL 21926 ND
Abbreviations are: -GTP, -glutamyl transpeptide; PTH, parathyroid hormone; CRP, C-reactive protein; PCR, protein catabolic rate; TIBC, total iron binding
capacity; and ND, not determined. Data are expressed as mean  SE.
Fig. 2. Blood thioredoxin (TRX) and serum asparate aminotransferase
Fig. 3. Blood ferritin and oxidative stress markers in hepatitis C virus(AST) in dialysis patients with (A ) and without (B ) hepatitis C viremia
(HCV)-infected dialysis patients. Serum ferritin was significantly and(HCV). TRX was significantly and positively correlated with AST,
positively associated with thioredoxin (TRX) and malondialdehydeboth in patients with (N  59) and without hepatitis C virus infection
(MDA) in patients with chronic HCV infection (N  89).(N  85).
was not associated with either ALT (r  0.17, P  NS) TRX (r  0.26, P  0.02) (Fig. 3). However, transferrin
saturation, a percent of serum iron divided by total ironand -GTP (r  0.16, P  NS) in patients with HCV
viremia. TRX did not correlate with blood AFP or binding capacity, did not correlate with serum TRX in
patients with HCV infection. No association was foundPIVKA-II.
HCV RNA amounts were ranged from 0.5 to 850.0 between TRX and ferritin or transferrin saturation in
patients without anti-HCV antibodies.KIU/mL (median, 180.0 KIU/mL). A significant positive
relationship was found between HCV RNA and ALT Seventeen out of 144 patients had received intermit-
tent iron supplement at the start of this study. TRX was(r  0.33, P  0.01), AST (r  0.20, P  0.07) and AFP
(r  0.34, P  0.01). However, HCV RNA level did not significantly higher in HCV-negative patients receiving
iron treatment (91.8 12.1 ng/mL, N 10) than in thosecorrelate with blood TRX or MDA.
not receiving iron injections (65.2  2.7 ng/mL, N  49)
Iron and blood TRX (P  0.01, Fig. 4) despite the same serum ferritin in both
groups (310  49 vs. 274  46 ng/mL, P  NS). TRXIn HCV-positive patients, serum ferritin was signifi-
cantly correlated with MDA (r  0.25, P  0.02) and was also higher in HCV-positive patients receiving iron
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Table 2. Stepwise regression analysis of laboratory variables on
blood thioredoxin (TRX) in hemodialysis patients with hepatitis C
virus (HCV) infection and without HCV infection
Variables Coefficient SE F-value
HCV-positive patients
Time on hemodialysis 0.834 0.356 5.474
Ferritin 0.020 0.009 4.746
R  0.351, F to remove  4.00
HCV-negative patients
Age 0.646 0.188 11.185
Iron infusion (yes 1) 24.055 7.408 10.543
R  0.554, F to remove  4.00
Fig. 4. Iron injection and blood thioredoxin (TRX) in hemodialysis
patients. Hemodialysis patients receiving weekly iron injection (40 mg,
intravenously) have a higher TRX level compared to those without
iron supplement, both in patients with and without hepatitis C virus receiving hemodialysis for more than 10 years [23  1(HCV) infection.
(11 to 32) years, N  59], suggesting a minor role of
hemodialysis duration on serum TRX in patients on
long-term hemodialysis. Finally, diabetes did not corre-
therapy (135.3  10.2 ng/mL, N  7) than those not late with blood TRX in hemodialysis patients, although
receiving iron (110.2  3.9 ng/mL, N  78) (P  0.06, a substantial increase in blood TRX has been observed
Fig. 4). There was no significant increase in aminotrans- in general diabetic patients compared to control subjects
ferases or -GTP levels in HCV-positive or negative (38 vs. 21 ng/mL) [16].
patients following iron therapy for 3 months (data not The source of the increased TRX in hemodialysis pa-
shown). tients, however, remains uncertain. In this study, blood
TRX in patients with chronic HCV hepatitis was muchDeterminants of serum TRX
higher in hemodialysis patients than general subjects
By stepwise multiple regression analysis, time on he- (mean, 34.5 ng/mL) [19]. In addition, serum TRX did not
modialysis, and blood ferritin were significant determi- correlate with serum ALT, a reliable marker of disease
nants of TRX in HCV-infected patients (Table 2). In activity in HCV-related hepatitis. However, half of the
HCV-negative patients, age and need for iron injection patients did have an ALT of more than 20 IU/L, a level
were significant indicators of serum TRX (Table 2). that can predict HCV infection in hemodialysis patients
[22]. Blood TRX was also unaffected by the amount of
HCV RNA. Taken together, these findings suggest thatDISCUSSION
elevated TRX may not be associated with hepatic cellRecently, blood TRX was shown to be elevated in
damage and may not be derived from damaged hepaticpatients with chronic liver diseases such as HCV infec-
cells in HCV-infected hemodialysis patients. A similartion, alcoholic liver disease and fatty liver, but not with
negative relationship between blood TRX and ALT washepatitis B virus infection [18–21]. Sumida et al [18]
found in HCV-infected nonhemodialysis patients withdemonstrated that serum TRX was significantly higher in
chronic hepatitis or liver cirrhosis [19]. However, thegeneral patients with chronic HCV hepatitis than healthy
liver contains the largest amount of TRX in human bodycontrols. They also found that blood TRX level was
[23, 24]. We found that blood TRX was positively corre-correlated with the severity of hepatic fibrosis and poor
lated with AST despite levels within the normal rangeresponsiveness to interferon- treatment. A reduction
(40 IU/L). A relatively strong relationship betweenin serum TRX by treatment with hepatoprotective drugs
blood TRX and AST was also noticed in patients withwas also observed in some HCV-infected patients [19].
HIV infection [11] and hepatic diseases such as alcoholicIn the current study, we found that serum TRX was
liver disease, fatty liver, and chronic HCV infectionelevated to a greater extent in hemodialysis patients with
[19, 20]. Therefore, additional studies will be needed tochronic HCV infection, suggesting that hemodialysis pa-
determine whether circulating TRX may be derived fromtients were under oxidative stress that was further exac-
intact hepatic cells and/or other nonliver cells.erbated by chronic HCV infection.
In this study, we found that serum TRX was increasedIn this study, TRX was positively correlated with age
to almost 70 ng/mL in HCV-negative hemodialysis pa-in HCV-negative dialysis patients, which may reflect en-
tients, which is about 2.5-fold higher than normal sub-hanced oxidative stress in the elderly. In contrast, time
jects. In part, the increment in TRX in hemodialysison hemodialysis was weakly but significantly correlated
patients may result from accumulation of TRX in thewith blood TRX, but only in HCV-positive patients.
However, this significance disappeared among patients circulation due to a reduction in renal clearance (12 kD
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molecular weight). However, a greater elevation of se- this study [33]. Finally, we could not determine whether
there was a direct effect of increased TRX in HCV-infectedrum TRX in response to oxidative tress was also noticed
in nonuremic patients with rheumatoid arthritis [13], pan- patients. In HIV-infected individuals, chronically high
levels of blood TRX has been suggested to block migra-creatic cancer [14], and severe burn injury [15] (mean,
86.8, 54.8, and 122.6 ng/mL, respectively). Since TRX is tion of protective cells to sites of pathogens, which may
impair host defense mechanisms and eventually shortensecreted by macrophages and T lymphocytes, and acts as
a chemoattractant for lymphocytes [25], increased serum patient survival [12]. Since blood TRX was higher in
HCC patients and correlated with hepatic fibrosis mark-TRX may be due to enhanced TRX secretion from acti-
vated blood monocytes under uremia. We also noted a ers such as hyaluronic acid, type IV collagen, and procol-
lagen III peptide [19], TRX may protect hepatocytessmall but significant reduction of serum TRX in patients
using a PS membrane (59.5  4.8 ng/mL, N  16), com- from HCV-induced oxidative stress damage, such as fi-
brogenesis and carcinogenesis. In addition, elevated TRXpared to those using a CTA (75.3  4.6 ng/mL, N  36)
membrane (P  0.05), in patients without HCV infec- may be associated with atherosclerosis, since TRX ex-
pression is increased in human coronary atherosclerotiction, suggesting that a biocompatible dialyzer membrane
may reduce serum TRX. lesions [34].
Iron deficiency is one of the major causes of rHuEPO
hyporesponsiveness in hemodialysis patients. So, the Na-
CONCLUSION
tional Kidney Foundation Dialysis Outcomes Quality
We found that blood TRX was elevated to a greaterInitiative (NKF-DOQI) recommends iron supplement
extent in hemodialysis patients with chronic HCV hepati-to maintain serum ferritin levels 100 ng/mL and trans-
tis. In addition, blood TRX was increased with higherferrin saturation ratio20% [26]. A substantially higher
baseline ferritin and intravenous iron infusion. However,serum ferritin level is necessary to sustain adequate re-
serum TRX was not associated with blood ALT, indicat-sponse to rHuEPO in hemodialysis patients with HCV
ing that blood TRX may not be involved in hepaticinfection compared to those without HCV infection (fer-
cellular damage in HCV-infected HD patients. Addi-ritin, 244 vs. 178 ng/mL) [27]. However, increased plasma
tional long-term studies are needed to explore the certi-MDA results from an elevated basal ferritin level and
fication of chronic elevation of blood TRX in the devel-intravenous iron therapy in hemodialysis patients [28–30].
opment of malignancy and/or arteriosclerosis in dialysisA single injection of 100 mg of iron at the beginning
patients.of hemodialysis rapidly increased blood MDA two- to
threefold from 30 minutes to 3 hours after the iron ad-
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